[HTML][HTML] Treatment of patients with metastatic cancer using a major histocompatibility complex class II–restricted T-cell receptor targeting the cancer germline antigen …
Journal of Clinical Oncology, 2017•ncbi.nlm.nih.gov
Purpose Adoptive transfer of genetically modified T cells is being explored as a treatment for
patients with metastatic cancer. Most current strategies use genes that encode major
histocompatibility complex (MHC) class I–restricted T-cell receptors (TCRs) or chimeric
antigen receptors to genetically modify CD8+ T cells or bulk T cells for treatment. Here, we
evaluated the safety and efficacy of an adoptive CD4+ T-cell therapy using an MHC class II–
restricted, HLA-DPB1* 0401–restricted TCR that recognized the cancer germline antigen …
patients with metastatic cancer. Most current strategies use genes that encode major
histocompatibility complex (MHC) class I–restricted T-cell receptors (TCRs) or chimeric
antigen receptors to genetically modify CD8+ T cells or bulk T cells for treatment. Here, we
evaluated the safety and efficacy of an adoptive CD4+ T-cell therapy using an MHC class II–
restricted, HLA-DPB1* 0401–restricted TCR that recognized the cancer germline antigen …
Abstract
Purpose
Adoptive transfer of genetically modified T cells is being explored as a treatment for patients with metastatic cancer. Most current strategies use genes that encode major histocompatibility complex (MHC) class I–restricted T-cell receptors (TCRs) or chimeric antigen receptors to genetically modify CD8+ T cells or bulk T cells for treatment. Here, we evaluated the safety and efficacy of an adoptive CD4+ T-cell therapy using an MHC class II–restricted, HLA-DPB1* 0401–restricted TCR that recognized the cancer germline antigen, MAGE-A3 (melanoma-associated antigen-A3).
ncbi.nlm.nih.gov